CN104714030A - Urine detection kit for cervical cancer and using method of urine detection kit - Google Patents
Urine detection kit for cervical cancer and using method of urine detection kit Download PDFInfo
- Publication number
- CN104714030A CN104714030A CN201510097778.3A CN201510097778A CN104714030A CN 104714030 A CN104714030 A CN 104714030A CN 201510097778 A CN201510097778 A CN 201510097778A CN 104714030 A CN104714030 A CN 104714030A
- Authority
- CN
- China
- Prior art keywords
- solution
- container
- detection kit
- urine detection
- dtnb
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57411—Specifically defined cancers of cervix
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Chemical & Material Sciences (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Cell Biology (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
The invention discloses a urine detection kit for cervical cancer. The urine detection kit comprises a container 1 and a container 2, wherein the container 1 is used for accommodating 2 milliliters of DTNB solution, and the container 2 is used for accommodating 2 milliliters of phosphotungstic acid solution. The invention further discloses a using method of the kit. The using method comprises the following steps: receiving 1 milliliter of first morning urine of a subject, adding dropwise the first morning urine into the container with the DTNB solution, leaving the mixture to stand for 2 to 5 minutes, then adding the mixture into the container with the phosphotungstic acid solution, leaving the mixed solution to stand for 2 to 5 minutes, and observing whether the color of the mixed solution changes or not. According to the urine detection kit and the using method, whether the subject suffers from cervical cancer or not can be conveniently and rapidly judged by color development reaction.
Description
Technical field
The present invention relates to external diagnosis reagent field, specifically, relate to a kind of cervical carcinoma urine detection kit and using method thereof.
Background technology
Early detection is the key for the treatment of tumour, and the development of tumour is divided into double teacher: optimum, tumour cell starting period, tumour are early stage, tumour mid-term, late period.The fearful part of cancer, is just front three phases, and iconography cannot detect at all, even if arrived tumour mid-term, also only has very professional doctor just can measure with more advanced equipment.The research of the World Health Organization (WHO) is thought: the cancer of current 1/3 can be prevented; The cancer of 1/3 can extend patient vitals by active treatment; The cancer of 1/3 can by early detection, early diagnosis, early treatment and fully recovering.
Cervical carcinoma is modal gynecologic malignant tumor.The carcinoma in situ age occurred frequently is 30 ~ 35 years old, and infiltrating carcinoma is 45 ~ 55 years old, and its morbidity in recent years has the trend of rejuvenation.The method being most commonly used to cervical lesion screening is at present cervical cytological examination, but detecting step very complicated, invasive is high, and charge is higher, makes the examination of cervical carcinoma be difficult to popularize.A large amount of non-protein sulfydryl is there is in having bibliographical information cervical cancer patient to urinate, also report and cervix cancer rapid self-inspection kit (FST-SH) can be used to detect non-protein sulfydryl in Urine in Patients, thus judge whether patient suffers from the risk (" detect sulfydryl sieve in urine and examine the clinical meaning of cervical carcinoma and precancerous lesion " of cervical carcinoma, " Clinical Oncology impurity ", 13 volume o. 11ths by the end of November in 2008,974-978 page).But this section of document does not disclose concrete composition and the preparation method of FSH-SH.
All disclose the kit detecting sulfydryl in Chinese patent CN202092960U and CN104181155A, but in these two sections of documents, all employ the mercuric chloride (that is, mercuric chloride) with serious health hazards, to the health of operator, there is certain risk.CN104198404A discloses a kind of cervical carcinoma screening rapid quantitative detection reagent box, wherein use DTNB as developer, but DTNB is the sulfydryl detected in protein, polypeptide, and this method needs to use biochemical instruments to detect, the general family operation of inapplicable patient.
Summary of the invention
Object of the present invention is just to provide a kind of cervical carcinoma urine detection kit and using method thereof that a kind of detection sensitivity is high, accuracy is good, judges whether to suffer from cervical carcinoma for sulfydryl in human body urine.
Cervical carcinoma urine detection kit of the present invention, comprises container 1 and container 2, wherein contains 2ml DTNB solution in container 1, containing 2ml Salkowski's solution in container 2.
Wherein DTNB solution is prepared as follows: first prepare Tris-glycine buffer, containing 1.04g Tris(trishydroxymethylaminomethane in every 100ml solution), 0.69g glycocoll, 0.12g EDTA(ethylenediamine tetraacetic acid), pH=8.0, by 0.4g DTNB(namely, 5,5 '-two thiobis (2-nitrobenzoic acid)) be dissolved in the above-mentioned damping fluid of 100ml, form DTNB solution.
Wherein Salkowski's solution is prepared as follows: first prepare acetate buffer, and 2 mol/L sodium acetate solution 98ml add 2mol/L acetum 2ml and mix, and is dissolved in by 4g phosphotungstic acid in the above-mentioned damping fluid of 100ml, forms Salkowski's solution.
Cervical carcinoma urine detection kit of the present invention, its using method is: get experimenter's urina sanguinis 1ml, is first added drop-wise in the container containing 2ml DTNB solution, leave standstill 2-5 minute, then whether add in the container containing 2ml Salkowski's solution, leave standstill 2-5 minute, observing solution has color to change.
Criterion: if 1 without color change, be judged as feminine gender, does not have cervical carcinoma in prompting subject; If 2 colors transfer blueness to, be judged as the positive, in prompting subject, have cervical carcinoma.
DTNB is the reagent for free sulfhydryl groups in test protein in Ellman reaction, and urine is first reacted with it by the application, the free sulfhydryl groups in conjugated protein.If experimenter suffers from cervical carcinoma, then there is a large amount of non-protein sulfhydryl in urine, sulfydryl is reductive agent, phosphotungstic acid can be made to be reduced into tungsten blue and in blue in sour environment, and then infers that patient suffers from cervical carcinoma.Therefore, reagent of the present invention is applicable to suffering from albuminuretic patient equally, improves the scope of application of reagent.Eliminate the interference of protein sulfhydryl simultaneously, also improve the accuracy of test.
Therefore, the invention provides a kind of cervical carcinoma urine detection kit and using method thereof, it, by detecting the sulfydryl in Urine in Patients, judges whether patient suffers from cervical carcinoma.This reagent composition is simple, only needs two kinds of main agents.Easy to operate, patient is in and can operates, simple and fast.And by DTNB Binding proteins sulfydryl, reduce interference, therefore positive rate and accuracy rate high.
Embodiment
Describe embodiments of the present invention below by embodiment, one of ordinary skill in the art appreciates that these specific embodiments only show the enforcement technical scheme selected to reach object of the present invention, is not the restriction to technical scheme.According to instruction of the present invention, be obvious in conjunction with the improvement of prior art to technical solution of the present invention, all belong to the scope of protection of the invention.
A kind of cervical carcinoma urine detection kit, comprises container 1 and container 2, wherein contains 2ml DTNB solution in container 1, containing 2ml Salkowski's solution in container 2.
Wherein DTNB solution is prepared as follows: first prepare Tris-glycine buffer, containing 1.04g Tris in every 100ml solution, 0.69g glycocoll, 0.12g EDTA, pH=8.0, by 0.4g DTNB(namely, 5,5 '-two thiobis (2-nitrobenzoic acid)) be dissolved in the above-mentioned damping fluid of 100ml, form DTNB solution.
Wherein Salkowski's solution is prepared as follows: first prepare acetate buffer, and 2 mol/L sodium acetate solution 98ml add 2mol/L acetum 2ml and mix, and is dissolved in by 4g phosphotungstic acid in the above-mentioned damping fluid of 100ml, forms Salkowski's solution.
A kind of using method of cervical carcinoma urine detection kit: get experimenter's urina sanguinis 1ml, first be added drop-wise in the container containing 2ml DTNB solution, leave standstill 2-5 minute, then add in the container containing 2ml Salkowski's solution, whether leave standstill 2-5 minute, observing solution has color to change.
Through the clinical verification of tumour hospital, 320 examples are in the Patients with Cervical Cancer made a definite diagnosis through histology and detect 298 examples for positive patient, and accuracy rate (coincidence rate) reaches 93.1%.
Cervical carcinoma urine detection kit of the present invention makes simple, with low cost, only needs two kinds of main agents DTNB and phosphotungstic acid.And use DTNB to eliminate the interference of protein sulfhydryl to testing result, improve the accuracy of testing result.Do not use the reagent with serious health hazards, safer for operator.And without the need to complex instrument, colour developing is obvious, easy observations.
The foregoing is only the preferred embodiments of the present invention, not any formal and substantial restriction is made to the present invention.Those skilled in the art, not departing from the scope of technical solution of the present invention, the change made, modifies and is Equivalent embodiments of the present invention with the equivalent variations of differentiation when utilizing disclosed above technology contents; Meanwhile, all according to substantial technological of the present invention to the change of any equivalent variations that above embodiment is done, modify with differentiation etc. all in the scope defined by claim of the present invention.
Claims (4)
1. a cervical carcinoma urine detection kit, is characterized in that, comprises container 1 and container 2, wherein contains 2ml DTNB solution in container 1, containing 2ml Salkowski's solution in container 2.
2. cervical carcinoma urine detection kit according to claim 1, it is characterized in that, the wherein following preparation of DTNB solution: first prepare Tris-glycine buffer, containing 1.04g Tris in every 100ml solution, 0.69g glycocoll, 0.12g EDTA, pH=8.0,0.4g DTNB is dissolved in the above-mentioned damping fluid of 100ml, forms DTNB solution.
3. the cervical carcinoma urine detection kit described in claim 1 or 2, it is characterized in that, wherein Salkowski's solution is prepared as follows: first prepare acetate buffer, 2mol/L sodium acetate solution 98ml adds 2mol/L acetum 2ml and mixes, 4g phosphotungstic acid is dissolved in the above-mentioned damping fluid of 100ml, forms Salkowski's solution.
4. the using method of the cervical carcinoma urine detection kit according to any one of claims 1 to 3, it is characterized in that, get experimenter's urina sanguinis 1ml, first be added drop-wise in the container containing DTNB solution, leave standstill 2-5 minute, then whether add in the container containing Salkowski's solution, leave standstill 2-5 minute, observing solution has color to change.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510097778.3A CN104714030B (en) | 2015-03-05 | 2015-03-05 | A kind of cervical cancer urine detection test kit |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510097778.3A CN104714030B (en) | 2015-03-05 | 2015-03-05 | A kind of cervical cancer urine detection test kit |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN104714030A true CN104714030A (en) | 2015-06-17 |
| CN104714030B CN104714030B (en) | 2016-06-22 |
Family
ID=53413538
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510097778.3A Expired - Fee Related CN104714030B (en) | 2015-03-05 | 2015-03-05 | A kind of cervical cancer urine detection test kit |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104714030B (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106226295A (en) * | 2016-07-05 | 2016-12-14 | 苏州锐霖生物科技有限公司 | A kind of urine sulfhydryl compound detectable and preparation method |
| CN110006883A (en) * | 2019-04-08 | 2019-07-12 | 深圳华创生物医药科技有限公司 | A kind of urine sulfhydryl compound mercury-free detection reagent and preparation method and application |
| CN110006884A (en) * | 2019-04-08 | 2019-07-12 | 深圳华创生物医药科技有限公司 | A kind of urine sulfhydryl compound mercury-free test strip and preparation method |
| CN110927156A (en) * | 2019-12-26 | 2020-03-27 | 欧迪玛(湖北)生物科技有限公司 | Urine detection kit for cervical cancer and preparation method thereof |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2372811A (en) * | 2001-02-14 | 2002-09-04 | Hector Cairns | Staining physiological samples |
| CN104181155A (en) * | 2014-08-10 | 2014-12-03 | 成都煦华生物科技有限公司 | Kit and preparation method thereof |
| CN104198404A (en) * | 2014-08-06 | 2014-12-10 | 福州艾维德生物医药有限公司 | Quick and quantitative detection kit for screening cervical cancer |
-
2015
- 2015-03-05 CN CN201510097778.3A patent/CN104714030B/en not_active Expired - Fee Related
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2372811A (en) * | 2001-02-14 | 2002-09-04 | Hector Cairns | Staining physiological samples |
| CN104198404A (en) * | 2014-08-06 | 2014-12-10 | 福州艾维德生物医药有限公司 | Quick and quantitative detection kit for screening cervical cancer |
| CN104181155A (en) * | 2014-08-10 | 2014-12-03 | 成都煦华生物科技有限公司 | Kit and preparation method thereof |
Non-Patent Citations (3)
| Title |
|---|
| P. PAVANA ET AL.: "ANTIHYPERGLYCEMIC AND ANTILIPIDPEROXIDATIVE EFFECTS OF TEPHROSIA PURPUREA SEED EXTRACT IN STREPTOZOTOCIN INDUCED DIABETIC RATS", 《INDIAN JOURNAL OF CLINICAL BIOCHEMISTRY》 * |
| 刘健等: "检测尿中巯基筛诊宫颈癌与癌前病变的临床意义", 《临床肿瘤学杂志》 * |
| 张光兴: "DTNB与蛋白质巯基的相互作用", 《河北大学学报（自然科学版）》 * |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106226295A (en) * | 2016-07-05 | 2016-12-14 | 苏州锐霖生物科技有限公司 | A kind of urine sulfhydryl compound detectable and preparation method |
| CN110006883A (en) * | 2019-04-08 | 2019-07-12 | 深圳华创生物医药科技有限公司 | A kind of urine sulfhydryl compound mercury-free detection reagent and preparation method and application |
| CN110006884A (en) * | 2019-04-08 | 2019-07-12 | 深圳华创生物医药科技有限公司 | A kind of urine sulfhydryl compound mercury-free test strip and preparation method |
| CN110927156A (en) * | 2019-12-26 | 2020-03-27 | 欧迪玛(湖北)生物科技有限公司 | Urine detection kit for cervical cancer and preparation method thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN104714030B (en) | 2016-06-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Crosbie et al. | The Manchester International Consensus Group recommendations for the management of gynecological cancers in Lynch syndrome | |
| Lemos et al. | Blastomycosis: organ involvement and etiologic diagnosis. A review of 123 patients from Mississippi | |
| CN104714030B (en) | A kind of cervical cancer urine detection test kit | |
| Kobori | Home testing for male factor infertility: a review of current options | |
| Chapuis et al. | Clinical accuracy in the diagnosis of small polyps using the flexible fiberoptic sigmoidoscope | |
| CN105115966B (en) | Thiol compound detection kit and preparation method and application in urine | |
| CN205484377U (en) | Detection kit | |
| Petrone et al. | Does cytotechnician training influence the accuracy of EUS-guided fine-needle aspiration of pancreatic masses? | |
| Glass et al. | Using molecular testing to improve the management of thyroid nodules with indeterminate cytology: an institutional experience with review of molecular alterations | |
| US20130231869A1 (en) | Apparatus for cancer diagnosis | |
| Terdiman | It is time to get serious about diagnosing Lynch syndrome (hereditary nonpolyposis colorectal cancer with defective DNA mismatch repair) in the general population | |
| CN107407680B (en) | For detecting the preparation including Organomercurial of disease | |
| CN107576652A (en) | Detection reagent of sulfhydryl compound and preparation method thereof and purposes in a kind of urine | |
| Samarasena et al. | EUS-guided through-the-needle biopsy for pancreatic cystic lesions | |
| CN104406975A (en) | Method for preparing detection reagent of para hydroxyl phenylalanine in urea | |
| CN109613278A (en) | A kind of vitamin A detection kit | |
| Underwood et al. | Variable response to radioactive iodine treatment in poorly differentiated thyroid carcinoma | |
| CN108949980A (en) | A kind of kit detecting hepatocellular carcinoma | |
| Hacker et al. | Molecular imaging and molecular diagnostics: two sides of the same coin? | |
| Díaz-Silván et al. | Clinical application of [18F] FDG PET/CT in follicular lymphoma | |
| Lu et al. | Primary lung cancer with radioiodine avidity: A thyroid cancer cohort study | |
| Mohling et al. | Intestinal Permeability and Endometriosis: A pilot investigation | |
| CN106226295A (en) | A kind of urine sulfhydryl compound detectable and preparation method | |
| Pignon et al. | Hyperthyroidism in a guinea pig (Cavia porcellus) | |
| Cruz-Hernández et al. | Initial evaluation of dual-energy computed tomography as an imaging biomarker for hepatic metastases from neuroendocrine tumor of the gastrointestinal tract |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20160622 Termination date: 20210305 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |